Hmdb loader
Record Information
Version5.0
StatusExpected but not Quantified
Creation Date2012-09-06 15:16:51 UTC
Update Date2022-03-07 02:51:53 UTC
HMDB IDHMDB0015149
Secondary Accession Numbers
  • HMDB15149
Metabolite Identification
Common NameBalsalazide
DescriptionBalsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name 'Colazal' in the US and 'Colazide' in the UK. The chemical name is (E)-5-[[-4-(2-carboxyethyl) aminocarbonyl] phenyl]azo] -2-hydroxybenzoic acid. It is usually administered as the disodium salt. Balsalazide releases mesalazine, also known as 5-aminosalicylic acid, or 5-ASA, in the large intestine. Its advantage over that drug in the treatment of Ulcerative colitis is believed to be the delivery of the active agent past the small intestine to the large intestine, the active site of ulcerative colitis.
Structure
Data?1582753264
Synonyms
ValueSource
(e)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoic acidChEBI
(e)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylic acidChEBI
3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylic acidChEBI
5-[4-(2-Carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoic acidChEBI
BalsalazidaChEBI
BalsalazidoChEBI
BalsalazidumChEBI
(e)-5-((4-(((2-Carboxyethyl)amino)carbonyl)phenyl)azo)-2-hydroxybenzoateGenerator
(e)-5-({p-[(2-carboxyethyl)carbamoyl]phenyl}azo)-2-salicylateGenerator
3-(2-{4-[(2-carboxyethyl)carbamoyl]phenyl}hydrazinylidene)-6-oxocyclohexa-1,4-diene-1-carboxylateGenerator
5-[4-(2-Carboxy-ethylcarbamoyl)-phenylazo]-2-hydroxy-benzoateGenerator
Balsalazide disodiumHMDB
Chemical FormulaC17H15N3O6
Average Molecular Weight357.3175
Monoisotopic Molecular Weight357.096085227
IUPAC Name5-[(E)-2-{4-[(2-carboxyethyl)carbamoyl]phenyl}diazen-1-yl]-2-hydroxybenzoic acid
Traditional Namebalsalazide
CAS Registry Number80573-04-2
SMILES
OC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O
InChI Identifier
InChI=1S/C17H15N3O6/c21-14-6-5-12(9-13(14)17(25)26)20-19-11-3-1-10(2-4-11)16(24)18-8-7-15(22)23/h1-6,9,21H,7-8H2,(H,18,24)(H,22,23)(H,25,26)/b20-19+
InChI KeyIPOKCKJONYRRHP-FMQUCBEESA-N
Chemical Taxonomy
Description Belongs to the class of organic compounds known as azobenzenes. These are organonitrogen aromatic compounds that contain a central azo group, where each nitrogen atom is conjugated to a benzene ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzobenzenes
Sub ClassNot Available
Direct ParentAzobenzenes
Alternative Parents
Substituents
  • Azobenzene
  • Beta amino acid or derivatives
  • Hydroxybenzoic acid
  • Salicylic acid or derivatives
  • Salicylic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzamide
  • Benzoyl
  • 1-hydroxy-2-unsubstituted benzenoid
  • Phenol
  • Benzenoid
  • Dicarboxylic acid or derivatives
  • Monocyclic benzene moiety
  • Vinylogous acid
  • Azo compound
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Carboxylic acid
  • Carbonyl group
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Organic oxide
  • Organooxygen compound
  • Organic oxygen compound
  • Organopnictogen compound
  • Organonitrogen compound
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Ontology
Physiological effectNot Available
Disposition
ProcessNot Available
Role
Physical Properties
StateSolid
Experimental Molecular Properties
PropertyValueReference
Melting PointNot AvailableNot Available
Boiling PointNot AvailableNot Available
Water Solubility0.062 g/LNot Available
LogP1.3Not Available
Experimental Chromatographic PropertiesNot Available
Predicted Molecular Properties
PropertyValueSource
Water Solubility0.062 g/LALOGPS
logP3.37ALOGPS
logP3.17ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)3.06ChemAxon
pKa (Strongest Basic)-0.033ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area148.65 ŲChemAxon
Rotatable Bond Count7ChemAxon
Refractivity94.37 m³·mol⁻¹ChemAxon
Polarizability35.98 ųChemAxon
Number of Rings2ChemAxon
BioavailabilityYesChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted Chromatographic Properties

Predicted Collision Cross Sections

PredictorAdduct TypeCCS Value (Å2)Reference
DeepCCS[M+H]+184.08430932474
DeepCCS[M-H]-181.72630932474
DeepCCS[M-2H]-215.67730932474
DeepCCS[M+Na]+190.90530932474
AllCCS[M+H]+179.732859911
AllCCS[M+H-H2O]+176.932859911
AllCCS[M+NH4]+182.232859911
AllCCS[M+Na]+182.932859911
AllCCS[M-H]-181.332859911
AllCCS[M+Na-2H]-180.932859911
AllCCS[M+HCOO]-180.732859911

Predicted Retention Times

Underivatized

Chromatographic MethodRetention TimeReference
Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022.4.16 minutes32390414
Predicted by Siyang on May 30, 202210.8975 minutes33406817
Predicted by Siyang using ReTip algorithm on June 8, 20224.26 minutes32390414
AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid143.3 seconds40023050
Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid1498.0 seconds40023050
Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid209.5 seconds40023050
Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid92.2 seconds40023050
Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid152.6 seconds40023050
RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid57.8 seconds40023050
Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid310.1 seconds40023050
BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid409.8 seconds40023050
HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate)141.3 seconds40023050
UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid658.5 seconds40023050
BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid364.0 seconds40023050
UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid1369.3 seconds40023050
SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid248.7 seconds40023050
RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid308.2 seconds40023050
MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate454.7 seconds40023050
KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA174.6 seconds40023050
Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water306.6 seconds40023050

Predicted Kovats Retention Indices

Underivatized

MetaboliteSMILESKovats RI ValueColumn TypeReference
BalsalazideOC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O4846.3Standard polar33892256
BalsalazideOC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O3152.1Standard non polar33892256
BalsalazideOC(=O)CCNC(=O)C1=CC=C(C=C1)\N=N\C1=CC=C(O)C(=C1)C(O)=O3669.3Semi standard non polar33892256

Derivatized

Derivative Name / StructureSMILESKovats RI ValueColumn TypeReference
Balsalazide,1TMS,isomer #1C[Si](C)(C)OC(=O)CCNC(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O)=C2)C=C13884.3Semi standard non polar33892256
Balsalazide,1TMS,isomer #2C[Si](C)(C)OC1=CC=C(/N=N/C2=CC=C(C(=O)NCCC(=O)O)C=C2)C=C1C(=O)O3899.9Semi standard non polar33892256
Balsalazide,1TMS,isomer #3C[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(C(=O)NCCC(=O)O)C=C2)=CC=C1O3881.6Semi standard non polar33892256
Balsalazide,1TMS,isomer #4C[Si](C)(C)N(CCC(=O)O)C(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O)=C2)C=C13808.7Semi standard non polar33892256
Balsalazide,2TMS,isomer #1C[Si](C)(C)OC(=O)CCNC(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C)C(C(=O)O)=C2)C=C13847.9Semi standard non polar33892256
Balsalazide,2TMS,isomer #2C[Si](C)(C)OC(=O)CCNC(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O[Si](C)(C)C)=C2)C=C13797.0Semi standard non polar33892256
Balsalazide,2TMS,isomer #3C[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O)=C2)C=C1)[Si](C)(C)C3613.8Semi standard non polar33892256
Balsalazide,2TMS,isomer #4C[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(C(=O)NCCC(=O)O)C=C2)=CC=C1O[Si](C)(C)C3859.9Semi standard non polar33892256
Balsalazide,2TMS,isomer #5C[Si](C)(C)OC1=CC=C(/N=N/C2=CC=C(C(=O)N(CCC(=O)O)[Si](C)(C)C)C=C2)C=C1C(=O)O3725.8Semi standard non polar33892256
Balsalazide,2TMS,isomer #6C[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(C(=O)N(CCC(=O)O)[Si](C)(C)C)C=C2)=CC=C1O3621.1Semi standard non polar33892256
Balsalazide,3TMS,isomer #1C[Si](C)(C)OC(=O)CCNC(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)=C2)C=C13783.5Semi standard non polar33892256
Balsalazide,3TMS,isomer #2C[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C)C(C(=O)O)=C2)C=C1)[Si](C)(C)C3598.4Semi standard non polar33892256
Balsalazide,3TMS,isomer #3C[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O[Si](C)(C)C)=C2)C=C1)[Si](C)(C)C3532.0Semi standard non polar33892256
Balsalazide,3TMS,isomer #4C[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(C(=O)N(CCC(=O)O)[Si](C)(C)C)C=C2)=CC=C1O[Si](C)(C)C3613.3Semi standard non polar33892256
Balsalazide,4TMS,isomer #1C[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)=C2)C=C1)[Si](C)(C)C3577.8Semi standard non polar33892256
Balsalazide,4TMS,isomer #1C[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)=C2)C=C1)[Si](C)(C)C3449.0Standard non polar33892256
Balsalazide,4TMS,isomer #1C[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C)C(C(=O)O[Si](C)(C)C)=C2)C=C1)[Si](C)(C)C4085.5Standard polar33892256
Balsalazide,1TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)CCNC(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O)=C2)C=C14158.0Semi standard non polar33892256
Balsalazide,1TBDMS,isomer #2CC(C)(C)[Si](C)(C)OC1=CC=C(/N=N/C2=CC=C(C(=O)NCCC(=O)O)C=C2)C=C1C(=O)O4198.2Semi standard non polar33892256
Balsalazide,1TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(C(=O)NCCC(=O)O)C=C2)=CC=C1O4172.3Semi standard non polar33892256
Balsalazide,1TBDMS,isomer #4CC(C)(C)[Si](C)(C)N(CCC(=O)O)C(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O)=C2)C=C14093.1Semi standard non polar33892256
Balsalazide,2TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)CCNC(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O)=C2)C=C14357.5Semi standard non polar33892256
Balsalazide,2TBDMS,isomer #2CC(C)(C)[Si](C)(C)OC(=O)CCNC(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O[Si](C)(C)C(C)(C)C)=C2)C=C14286.3Semi standard non polar33892256
Balsalazide,2TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O)=C2)C=C1)[Si](C)(C)C(C)(C)C4172.8Semi standard non polar33892256
Balsalazide,2TBDMS,isomer #4CC(C)(C)[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(C(=O)NCCC(=O)O)C=C2)=CC=C1O[Si](C)(C)C(C)(C)C4327.4Semi standard non polar33892256
Balsalazide,2TBDMS,isomer #5CC(C)(C)[Si](C)(C)OC1=CC=C(/N=N/C2=CC=C(C(=O)N(CCC(=O)O)[Si](C)(C)C(C)(C)C)C=C2)C=C1C(=O)O4238.4Semi standard non polar33892256
Balsalazide,2TBDMS,isomer #6CC(C)(C)[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(C(=O)N(CCC(=O)O)[Si](C)(C)C(C)(C)C)C=C2)=CC=C1O4146.9Semi standard non polar33892256
Balsalazide,3TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)CCNC(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)=C2)C=C14412.4Semi standard non polar33892256
Balsalazide,3TBDMS,isomer #2CC(C)(C)[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O)=C2)C=C1)[Si](C)(C)C(C)(C)C4325.9Semi standard non polar33892256
Balsalazide,3TBDMS,isomer #3CC(C)(C)[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O)C(C(=O)O[Si](C)(C)C(C)(C)C)=C2)C=C1)[Si](C)(C)C(C)(C)C4220.1Semi standard non polar33892256
Balsalazide,3TBDMS,isomer #4CC(C)(C)[Si](C)(C)OC(=O)C1=CC(/N=N/C2=CC=C(C(=O)N(CCC(=O)O)[Si](C)(C)C(C)(C)C)C=C2)=CC=C1O[Si](C)(C)C(C)(C)C4271.8Semi standard non polar33892256
Balsalazide,4TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)=C2)C=C1)[Si](C)(C)C(C)(C)C4361.2Semi standard non polar33892256
Balsalazide,4TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)=C2)C=C1)[Si](C)(C)C(C)(C)C4104.3Standard non polar33892256
Balsalazide,4TBDMS,isomer #1CC(C)(C)[Si](C)(C)OC(=O)CCN(C(=O)C1=CC=C(/N=N/C2=CC=C(O[Si](C)(C)C(C)(C)C)C(C(=O)O[Si](C)(C)C(C)(C)C)=C2)C=C1)[Si](C)(C)C(C)(C)C4264.6Standard polar33892256
Spectra

GC-MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted GC-MSPredicted GC-MS Spectrum - Balsalazide GC-MS (Non-derivatized) - 70eV, Positivesplash10-0ldi-1393000000-af92622c6ce32e802a992017-09-01Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Balsalazide GC-MS (3 TMS) - 70eV, Positivesplash10-052f-2239460000-dd6d65f067d80197bd6e2017-10-06Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Balsalazide GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum
Predicted GC-MSPredicted GC-MS Spectrum - Balsalazide GC-MS (Non-derivatized) - 70eV, PositiveNot Available2021-10-12Wishart LabView Spectrum

MS/MS Spectra

Spectrum TypeDescriptionSplash KeyDeposition DateSourceView
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 10V, Positive-QTOFsplash10-05mo-1359000000-5ac19318b9222056db992016-08-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 20V, Positive-QTOFsplash10-01b9-4194000000-a389ca20ea5f71b14f1b2016-08-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 40V, Positive-QTOFsplash10-00or-9460000000-058a3d277554ae6ad3a02016-08-01Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 10V, Negative-QTOFsplash10-0r00-0859000000-0815df00a696a3bf2ef92016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 20V, Negative-QTOFsplash10-0cdl-1596000000-f30b936242fc2a51a3bc2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 40V, Negative-QTOFsplash10-0a4i-1920000000-ab19fc8210a3b9bf159a2016-08-03Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 10V, Positive-QTOFsplash10-014i-0090000000-938e67d0a29d75e915602021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 20V, Positive-QTOFsplash10-0297-0094000000-71c0a9165a9dbb26d8ed2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 40V, Positive-QTOFsplash10-0fvi-0590000000-6f84da2d9032ab43467d2021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 10V, Negative-QTOFsplash10-0a4i-0019000000-5cde35cdf9191a2d07212021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 20V, Negative-QTOFsplash10-001l-0092000000-e9ef5ce26a4f3979c2122021-10-11Wishart LabView Spectrum
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - Balsalazide 40V, Negative-QTOFsplash10-0006-2290000000-1ff988f1dc562e4db92f2021-10-11Wishart LabView Spectrum
Biological Properties
Cellular Locations
  • Cytoplasm
  • Membrane
Biospecimen Locations
  • Blood
  • Urine
Tissue LocationsNot Available
Pathways
Normal Concentrations
BiospecimenStatusValueAgeSexConditionReferenceDetails
BloodExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01014 details
UrineExpected but not QuantifiedNot QuantifiedNot AvailableNot AvailableTaking drug identified by DrugBank entry DB01014 details
Abnormal Concentrations
Not Available
Predicted Concentrations
BiospecimenValueOriginal ageOriginal sexOriginal conditionComments
Blood0.000 uMAdult (>18 years old)BothNormalPredicted based on drug qualities
Blood0.000 umol/mmol creatinineAdult (>18 years old)BothNormalPredicted based on drug qualities
Associated Disorders and Diseases
Disease ReferencesNone
Associated OMIM IDsNone
DrugBank IDDB01014
Phenol Explorer Compound IDNot Available
FooDB IDNot Available
KNApSAcK IDNot Available
Chemspider ID10662422
KEGG Compound IDNot Available
BioCyc IDNot Available
BiGG IDNot Available
Wikipedia LinkBalsalazide
METLIN IDNot Available
PubChem CompoundNot Available
PDB IDNot Available
ChEBI ID267413
Food Biomarker OntologyNot Available
VMH IDNot Available
MarkerDB IDNot Available
Good Scents IDNot Available
References
Synthesis ReferenceNot Available
Material Safety Data Sheet (MSDS)Not Available
General References
  1. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890 ]
  2. Ragunath K, Williams JG: Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther. 2001 Oct;15(10):1549-54. [PubMed:11563993 ]

Enzymes

General function:
Involved in metal ion binding
Specific function:
Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.
Gene Name:
ALOX5
Uniprot ID:
P09917
Molecular weight:
77982.595
References
  1. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890 ]
  2. Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K: 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Agents Actions. 1992;Spec No:C37-46. [PubMed:1359745 ]
General function:
Involved in peroxidase activity
Specific function:
Mediates the formation of prostaglandins from arachidonate. May have a role as a major mediator of inflammation and/or a role for prostanoid signaling in activity-dependent plasticity.
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular weight:
68995.625
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890 ]
  4. Stolfi C, Fina D, Caruso R, Caprioli F, Sarra M, Fantini MC, Rizzo A, Pallone F, Monteleone G: Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol. 2008 Feb 1;75(3):668-76. Epub 2007 Sep 29. [PubMed:17981262 ]
  5. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
General function:
Involved in peroxidase activity
Specific function:
May play an important role in regulating or promoting cell proliferation in some normal and neoplastically transformed cells.
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular weight:
68685.82
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Wiggins JB, Rajapakse R: Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1279-84. doi: 10.1517/17425250903206996. [PubMed:19743890 ]
  4. Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4. [PubMed:12950415 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
General function:
Involved in DNA binding
Specific function:
Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis
Gene Name:
PPARG
Uniprot ID:
P37231
Molecular weight:
57619.6
References
  1. Tursi A: Balsalazide in treating colonic diseases. Expert Opin Drug Metab Toxicol. 2009 Dec;5(12):1555-63. doi: 10.1517/17425250903228842. [PubMed:19708827 ]
  2. Iacucci M, de Silva S, Ghosh S: Mesalazine in inflammatory bowel disease: a trendy topic once again? Can J Gastroenterol. 2010 Feb;24(2):127-33. [PubMed:20151072 ]
  3. Desreumaux P, Ghosh S: Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006 Sep;24 Suppl 1:2-9. [PubMed:16939423 ]
  4. Linard C, Gremy O, Benderitter M: Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonist. J Pharmacol Exp Ther. 2008 Mar;324(3):911-20. Epub 2007 Dec 12. [PubMed:18077625 ]